GlassScriptPhysician profile
Yuriy Ivanov
NPI 1790026011
$19,565.36
in general payments reported to CMS, 2019-2025
35 companies · $2,491 in 2025
The $2,491 reported for 2025 was more than what 83% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $1,555 · 2021: $5,411 · 2022: $4,533 · 2023: $1,987 · 2024: $2,320 · 2025: $2,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,531 · Travel and Lodging: $3,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,531.49 |
| Travel and Lodging | $3,266.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,883.75 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Boston Scientific Corporation | $4,374.79 | 2020-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $2,544.14 | 2021-2025 | Eterna |
| Nevro Corp. | $1,629.74 | 2019-2024 | Senza |
| Si-Bone, INC. | $717.27 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $665.78 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $375.62 | 2019-2021 | |
| Spr Therapeutics, INC | $317.26 | 2021-2025 | Sprint Pns System |
| Daiichi Sankyo INC. | $253.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $238.88 | 2020-2021 | |
| Biotronik Nro, INC. | $185.63 | 2025 | Prospera |
| Horizon Therapeutics Plc | $178.01 | 2020-2021 | |
| Globus Medical, INC. | $173.92 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.37 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $168.47 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $161.63 | 2025 | Optablate, Spinejack |
| Pfizer INC. | $149.97 | 2019-2020 | |
| Vertos Medical, INC. | $147.87 | 2022 | |
| Allergan, INC. | $147.15 | 2020-2021 | |
| Abbvie INC. | $138.29 | 2021-2024 | |
| Lilly USA, LLC | $136.14 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $126.21 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2022 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pacira Therapeutics, INC. | $86.41 | 2019-2021 | |
| Redhill Biopharma INC. | $68.60 | 2020 | |
| Biodelivery Sciences International, INC. | $57.33 | 2020 | |
| Depuy Synthes Sales INC. | $53.55 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $52.31 | 2021 | |
| Sentynl Therapeutics, INC. | $39.02 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $29.24 | 2020 | |
| Indivior INC. | $22.49 | 2020 | |
| Ibsa Pharma INC. | $17.59 | 2021 | |
| Medtronic USA, INC. | $16.67 | 2019 | |
| Mml US, INC. | $16.25 | 2025 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuriy Ivanov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.